The main purpose of this study is to evaluate the effectiveness of technetium \[99mTc\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To evaluate the safety of technetium \[99mTc\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To explore the diagnostic threshold of technetium \[99mTc\]-H7ND injection for peritoneal metastasis of gastrointestinal malignant tumor.
Adults over 18 years of age (based on the time when the informed consent form was signed) can be male or female;
Subjects with gastrointestinal malignant tumor confirmed by histology/cytology;
Subjects to be surgically removed or explored;
The estimated survival time is ≥12 weeks;
None
Single group
Technetium [99mTc]-H7ND injection
DrugTechnetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
To evaluate the effectiveness of technetium [99mTc]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor
To evaluate whether the sensitivity of 99mTc-H7ND SPECT/CT in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor is better than that of enhanced CT by SOT.
Click on the lead sponsor to view all of their trials.
